VOR

Vor Biopharma Inc

Oct 06 • 04:00PM ET

35.69

-1.77 -4.74 %

Healthcare • Biotechnology • USA • NASD

Peers: BMY GILD MRNA REGN VRTX BLUE CRSP EDIT NTLA PFE

| Held by: VTI VXF AVSC DFAU DFSU DFAC CHNA

Index	-	P/E	-	EPS (ttm)	-273.28	Insider Own	50.43%	Shs Outstand	6.28M	Perf Week	-10.54%
Market Cap	244.13M	Forward P/E	-	EPS next Y	-9.85	Insider Trans	-64.38%	Shs Float	3.39M	Perf Month	-8.97%
Enterprise Value	41.15M	PEG	-	EPS next Q	-3.34	Inst Own	20.81%	Short Float	32.48%	Perf Quarter	-25.66%
Income	-1664.43M	P/S	-	EPS this Y	-668.37%	Inst Trans	-	Short Ratio	2.74	Perf Half Y	214.63%
Sales	0.00M	P/B	-	EPS next Y	96.23%	ROA	-959.44%	Short Interest	1.10M	Perf YTD	60.74%
Book/sh	-239.67	P/C	1.20	EPS next 5Y	28.43%	ROE	-125.43%	52W High	65.80 -45.77%	Perf Year	170.55%
Cash/sh	29.67	P/FCF	-	EPS past 3/5Y	3.38% -38.02%	ROIC	-	52W Low	2.62 1260.98%	Perf 3Y	-54.25%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	16.29% 12.32%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-686.12%	Oper. Margin	-	ATR (14)	4.57	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.49	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	48.62	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	3.49	EPS Q/Q	-2981.96%	SMA20	2.28%	Beta	2.09	Target Price	35.75
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-8.04%	Rel Volume	1.53	Prev Close	37.46
Employees	159	LT Debt/Eq	-	Earnings	Aug 07	SMA200	45.47%	Avg Volume	401.71K	Price	35.69
IPO	Feb 05, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-2765.36% -	Trades		Volume	611,375	Change	-4.74%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-24-25	Upgrade	Stifel	Hold → Buy	$55
Jun-30-25	Upgrade	H.C. Wainwright	Neutral → Buy	$3
Jul-26-22	Initiated	Wedbush	Outperform	$18
Apr-27-22	Initiated	Goldman	Neutral	$6
Dec-17-21	Initiated	H.C. Wainwright	Buy	$26
Dec-03-21	Initiated	Robert W. Baird	Outperform	$38
Dec-02-21	Initiated	Oppenheimer	Outperform	$30
Oct-19-21	Initiated	JMP Securities	Mkt Outperform	$40
Mar-25-21	Initiated	B. Riley Securities	Buy	$60
Mar-03-21	Initiated	Evercore ISI	Outperform	$48
Mar-03-21	Initiated	Barclays	Overweight	$56
Mar-02-21	Initiated	Stifel	Buy	$58
Mar-02-21	Initiated	Goldman	Sell	$19

Show Previous Ratings

Oct-03-25 04:01PM	Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-29-25 07:00AM	Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjogren's Disease Clinical Study at ACR Convergence 2025 (GlobeNewswire) +18.65%
Sep-23-25 08:00AM	Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer (GlobeNewswire) +11.97%
Sep-17-25 04:15PM	Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM (GlobeNewswire)
Sep-12-25 04:15PM	Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum (GlobeNewswire) -8.05%
08:00AM	Loading…
Sep-02-25 08:00AM	Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel (GlobeNewswire)
Aug-27-25 01:21PM	Vor Bio's Investigational Drug Scores Phase 3 Win In Autoimmune Kidney Disease Trial (Benzinga)
08:00AM	Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy (GlobeNewswire)
Aug-26-25 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-18-25 04:35PM	Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-13-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +21.69%
08:30AM	Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor (GlobeNewswire)
08:30AM	Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjogren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor (GlobeNewswire)
07:00AM	Vor says drug licensed from RemeGen succeeded in Sjögrens study (BioPharma Dive)
Aug-04-25 08:30AM	Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer (GlobeNewswire)
09:35AM	Loading…
Jul-29-25 09:35AM	Vor Biopharma (VOR) Jumps 10% on Addition of 2 CEOs to Board (Insider Monkey)
Jul-21-25 08:30AM	Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors (GlobeNewswire) -7.24%
Jul-20-25 12:35AM	H.C. Wainwright Upgrades Vor Biopharma (VOR) to a Buy, Sets a $3 Price Target (Insider Monkey)
Jul-18-25 04:00PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.14% -7.24%
Jul-17-25 08:30AM	Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer (GlobeNewswire) +12.26%
Jul-10-25 04:00PM	Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer (GlobeNewswire) -9.06% +8.23%
Jul-01-25 04:00PM	Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -11.73%
Jun-30-25 10:40AM	Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why (Zacks) +52.83%
Jun-26-25 11:22AM	Vor, with new CEO, changes course to target autoimmune disease (BioPharma Dive) +60.53%
02:00AM	PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement (Business Wire)
Jun-25-25 04:50PM	Vor Bio Announces $175 Million Private Placement (GlobeNewswire) +74.28%
04:45PM	Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset (GlobeNewswire)
May-08-25 08:30AM	Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value (GlobeNewswire) -70.12%
Apr-30-25 02:00AM	PureTech Announces Annual Results for Year Ended December 31, 2024 (Business Wire)
Mar-20-25 05:01PM	Vor Biopharma files for $350M mixed securities shelf (SeekingAlpha)
04:05PM	Loading…
04:05PM	Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update (GlobeNewswire)
Feb-13-25 08:00AM	Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials (GlobeNewswire)
Feb-03-25 08:00AM	Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference (GlobeNewswire) -5.63%
Jan-27-25 09:55AM	Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross (Zacks) -5.12%
Jan-08-25 09:00AM	Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors (GlobeNewswire)
Dec-28-24 09:27AM	Vor Biopharma Secures $55.6M for Cancer Therapy Trials (TipRanks)
Dec-27-24 02:43PM	Vor Bio Secures $55.6 Million in PIPE Financing, Shares Surge Nearly 47% (GuruFocus.com) +51.55%
09:00AM	Vor Bio Announces $55.6 Million Private Placement (GlobeNewswire)
Dec-09-24 07:30AM	Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design (GlobeNewswire) +26.89%
Nov-12-24 08:00AM	Vor Bio to Participate in the Stifel 2024 Healthcare Conference (GlobeNewswire)
Nov-07-24 04:05PM	Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update (GlobeNewswire) +14.85%
Sep-30-24 07:00AM	Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer (GlobeNewswire)
Sep-06-24 02:00AM	PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies (Business Wire) +10.06%
Sep-05-24 04:01PM	New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies (GlobeNewswire)
Aug-28-24 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 04:05PM	Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update (GlobeNewswire)
Aug-02-24 04:01PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.98% -7.51%
Jul-09-24 04:01PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-04-24 04:01PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.69%
May-13-24 09:22AM	Oppenheimer Adjusts Vor Biopharma Price Target to $10 From $15, Maintains Outperform Rating (MT Newswires)
May-09-24 10:54PM	VOR Stock Earnings: Vor Biopharma Beats EPS for Q1 2024 (InvestorPlace) -5.52%
04:05PM	Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update (GlobeNewswire)
May-06-24 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-03-24 04:01PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-02-24 04:01PM	Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors (GlobeNewswire)
Apr-04-24 08:32AM	Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock (Zacks)
Apr-01-24 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.17%
Mar-20-24 09:53PM	VOR Stock Earnings: Vor Biopharma Beats EPS for Q4 2023 (InvestorPlace) +8.89%
04:05PM	Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update (GlobeNewswire)
Mar-05-24 04:01PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-24 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-15-24 02:56PM	2 Strong Buy Penny Stocks That Could Rally All the Way to $10 (or More) (TipRanks)
Feb-07-24 08:00AM	Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-02-24 04:01PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.53%
Jan-19-24 08:22AM	Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study (Zacks) -8.30%
Jan-17-24 04:01PM	Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update (GlobeNewswire) +7.39%
Dec-21-23 04:01PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.11% -8.37%
Dec-01-23 04:01PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +11.98%
Nov-27-23 08:00AM	Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-09-23 04:01PM	Vor Bio Presents Positive Data Update on Trem-cel at HSCT Conference (GlobeNewswire) -5.38%
Nov-07-23 04:05PM	Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update (GlobeNewswire) +9.34% -6.53%
Nov-03-23 04:01PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.43%
08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-02-23 09:01AM	Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform (GlobeNewswire) +5.74%
Oct-03-23 04:01PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.63%
Sep-25-23 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-30-23 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 04:05PM	Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update (GlobeNewswire) +14.40%
Aug-01-23 08:00AM	Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Jun-09-23 04:03PM	Vor Bio's Trem-cel Shows Early Encouraging Data In Leukemia Patients (Benzinga) -6.19%
07:30AM	Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bios Platform (GlobeNewswire)
Jun-05-23 08:00AM	Vor Bio to Participate in the Goldman Sachs Healthcare Conference (GlobeNewswire)
May-11-23 04:05PM	Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update (GlobeNewswire)
Apr-19-23 02:42PM	We Think Vor Biopharma (NASDAQ:VOR) Can Afford To Drive Business Growth (Simply Wall St.)
Apr-18-23 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.82%
Mar-28-23 09:55AM	How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06% (Zacks)
Mar-23-23 04:01PM	Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update (GlobeNewswire) -6.08% +15.29%
Mar-07-23 05:52AM	Vor Biopharma Inc. (NASDAQ:VOR) Shares Could Be 43% Below Their Intrinsic Value Estimate (Simply Wall St.)
Feb-21-23 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-16-23 02:04PM	Vor Biopharma's Leukemia Cell Exhibits Favorable Engraftment Five Months Post-Transplant (Benzinga) -6.47%
12:00PM	First AML Patient Transplanted with Vor Bios Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg Cycles at Initial Dose Level (GlobeNewswire)
Jan-19-23 08:00AM	Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings (GlobeNewswire)
Jan-12-23 08:00AM	Vor Bio to Present at B. Riley Securities 3rd Annual Oncology Conference (GlobeNewswire)
Dec-16-22 06:40PM	Bath & Body Works and Vor Biopharma Stock See Action From Activist Investors (Barrons.com) -11.17%
Dec-07-22 07:45AM	Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million (GlobeNewswire) +41.86%
07:30AM	First AML Patient Successfully Transplanted with Vor Bios Investigational Trem-cel (VOR33) and Tolerated Mylotarg (GlobeNewswire)
Nov-30-22 10:35AM	2 Strong Buy Penny Stocks That Could Rally All the Way to $15 (TipRanks) +6.48%
Nov-22-22 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-10-22 04:15PM	Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update (GlobeNewswire) +5.03%
Nov-01-22 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Reprogrammed Interchange LLC	10% Owner	Oct 02 '25	Sale	39.83	32,451	1,292,457	1,605,209	Oct 03 09:12 PM
Reprogrammed Interchange LLC	10% Owner	Oct 03 '25	Sale	37.83	7,901	298,911	1,597,308	Oct 03 09:12 PM
Reprogrammed Interchange LLC	10% Owner	Oct 01 '25	Sale	39.19	1,400	54,870	1,637,660	Oct 03 09:12 PM
Reprogrammed Interchange LLC	10% Owner	Sep 16 '25	Sale	1.54	447,278	688,853	32,781,209	Sep 18 08:40 PM
Reprogrammed Interchange LLC	10% Owner	Sep 15 '25	Sale	1.64	400,000	656,320	33,228,487	Sep 15 05:17 PM
Reprogrammed Interchange LLC	10% Owner	Sep 12 '25	Sale	1.75	300,000	526,230	33,628,487	Sep 15 05:17 PM
Reprogrammed Interchange LLC	10% Owner	Sep 11 '25	Sale	1.83	284,805	521,421	33,928,487	Sep 15 05:17 PM
Reprogrammed Interchange LLC	10% Owner	Sep 08 '25	Sale	1.99	464,421	924,058	35,012,518	Sep 10 08:27 PM
Reprogrammed Interchange LLC	10% Owner	Sep 09 '25	Sale	2.00	449,226	898,632	34,563,292	Sep 10 08:27 PM
Reprogrammed Interchange LLC	10% Owner	Sep 10 '25	Sale	1.82	350,000	635,285	34,213,292	Sep 10 08:27 PM
Reprogrammed Interchange LLC	10% Owner	Sep 03 '25	Sale	2.00	554,612	1,107,061	36,329,955	Sep 05 06:51 PM
Reprogrammed Interchange LLC	10% Owner	Sep 04 '25	Sale	1.93	453,016	873,641	35,876,939	Sep 05 06:51 PM
Reprogrammed Interchange LLC	10% Owner	Sep 05 '25	Sale	1.97	400,000	787,280	35,476,939	Sep 05 06:51 PM
Reprogrammed Interchange LLC	10% Owner	Sep 03 '25	Proposed Sale	2.00	23,000,000	46,115,000		Sep 03 01:50 PM
Reprogrammed Interchange LLC	10% Owner	Aug 28 '25	Sale	2.01	806,351	1,621,975	36,884,567	Aug 29 06:05 PM
Reprogrammed Interchange LLC	10% Owner	Aug 27 '25	Sale	2.01	611,647	1,226,536	37,690,918	Aug 29 06:05 PM
Reprogrammed Interchange LLC	10% Owner	Aug 25 '25	Sale	2.12	387,346	819,740	38,586,755	Aug 27 05:25 PM
Reprogrammed Interchange LLC	10% Owner	Aug 26 '25	Sale	2.08	284,190	591,343	38,302,565	Aug 27 05:25 PM
Robert Ang	Officer	Aug 11 '25	Proposed Sale	1.98	18,382	36,407		Aug 11 04:05 PM
SVEN ANTE LUNDBERG	Director	Aug 04 '25	Proposed Sale	2.09	29,432	61,589		Aug 04 06:08 PM
Robert Ang	Officer	Jul 16 '25	Proposed Sale	2.10	197,937	415,391		Jul 16 04:07 PM
Robert Ang	Officer	Jul 15 '25	Proposed Sale	2.43	214,135	520,586		Jul 15 05:29 PM
Robert Ang	Officer	Jul 10 '25	Proposed Sale	2.33	596,885	1,388,091		Jul 10 04:22 PM
ROBERT ANG	Officer	Jul 02 '25	Proposed Sale	1.79	44,936	80,435		Jul 02 04:40 PM
ROBERT ANG	Officer	Jul 01 '25	Proposed Sale	1.72	40,468	69,613		Jul 01 04:58 PM
ROBERT ANG	Officer	Jun 30 '25	Proposed Sale	1.73	40,627	70,289		Jun 30 05:15 PM
Attar Eyal C.	CHIEF MEDICAL OFFICER	Feb 13 '25	Sale	1.42	2,227	3,162	126,625	Feb 18 04:20 PM
EYAL ATTAR	Officer	Feb 13 '25	Proposed Sale	1.38	2,227	3,073		Feb 13 04:32 PM
Attar Eyal C.	CHIEF MEDICAL OFFICER	Feb 10 '25	Sale	1.37	2,554	3,499	128,852	Feb 12 04:29 PM
EYAL ATTAR	Officer	Feb 10 '25	Proposed Sale	1.41	2,554	3,601		Feb 10 04:34 PM
Attar Eyal C.	CHIEF MEDICAL OFFICER	Dec 27 '24	Sale	1.25	10,334	12,918	81,439	Dec 31 04:15 PM
EYAL ATTAR	Officer	Dec 27 '24	Proposed Sale	0.84	10,334	8,660		Dec 27 04:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VOR

Vor Biopharma Inc

Upgrade your FINVIZ experience